Respiratory Syncytial Virus

The adjuvanted RSVPreF3 vaccine could prevent nearly 3 million symptomatic RSV-ARI cases among US older adults over 3 years’ time, according to study results.

Shared decision making with patients is a key component of RSV vaccination, which can bring challenges and opportunities.

The at-home test offers the availability to assess for all viruses using one tool.

Only 9% of older adults who reside in the United States had been vaccinated to protect themselves from RSV this fall and winter.

The finding highlighted the importance of RSV risks among older adults, and aids pharmacists’ awareness when patients are hesitant to receive the RSV vaccine.

The updated indication for the respiratory syncytial virus vaccine is for adults aged 50 to 59 with underlying conditions who are at an increased risk of contracting the virus.

The CDC recommends RSV vaccination for all adults aged 60 years and older.

Addressing complacency, confidence, and convenience are all crucial to increasing vaccine uptake.

Older adults, patients with weakened immune systems, individuals living in long-term facilities, and those with underlying cardiopulmonary disease are at a higher risk of developing severe RSV infection outcomes.

The burden of RSV in the older population is becoming highly recognized as studies have assessed higher-risk individuals in industrialized and developing countries.

Older adults without a Part D plan face costs ranging from $180 to $295 per shot.

The schedule includes RSV vaccination, along with updated versions of the COVID-19 vaccine.

RSV could interact with nerve cells, causing nerve damage and possible entry to the spinal cord.

If vaccination coverage was increased by 100%, outpatient care could be reduced by 81.2%, hospitalizations by 91.7%, and deaths by 91.3%.

The study highlights the ongoing need for health care providers to recommend respiratory illness vaccinations to increase protection among nursing home residents during the peak season of infection.

From newsworthy moments to groundbreaking research, these were the most-read respiratory syncytial virus-related articles on Pharmacy Times in 2023.

The most recent advances included an approved vaccine that could immunize both the elderly and pregnant women, along with the release of nirsevimab.

Arexvy shows efficacy in helping protect adults aged 50 to 59 years with an increased risk for respiratory syncytial virus lower respiratory tract disease.

RSV can create a problematic infection among children 12 months of age or younger, older adults, and in patients with immunocompromised conditions.

Engaging technicians in immunizations has been crucial to public health

Expert discuss access barriers for the COVID-19, respiratory syncytial virus, and influenza vaccines, and ways to facilitate uptake.

Pharmacists play a vital role in providing education and administering influenza, COVID-19, and RSV Vaccines

Community pharmacies and organizations can collaborate to tailor strategies and interventions and address the challenges and specific needs of the community.

By educating their patients on the provisions of the Inflation Reduction Act, pharmacists can have an even greater impact by increasing vaccine uptake in historically underserved groups.

Best practices to train staff and team members to engage patients and to ease the new vaccine offerings into the workflow are also discussed.

Pharmacists play a critical role in educating patients on RSV prevention, how to recognize early symptoms, and when to seek medical help.

The pharmacy is no longer considered to offer full service (or to be financially sustainable) without a robust vaccination practice.

This technique may be applied to transdermal applications, such as shot-free vaccines.

Approximately 57% of individuals who were shown a flowchart of the FDA vaccine approval process were very or somewhat likely to recommend a respiratory syncytial virus vaccine to a pregnant family member or friend compared to only 40% of those who were not shown the process.